$862 Million

argenx SE

Follow-on Offering

Bookrunner, January 2020

argenx SE

argenx SE is a late-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. argenx’s SIMPLE Antibody Platform, based on the powerful llama immune system, allows the Company to exploit novel and complex targets, and its three Fc engineering technologies are designed to enable argenx to expand the therapeutic index of its product candidates. argenx’s most advanced product candidate, efgartigimod (ARGX-113), has completed a Phase 3 ADAPT registrational trial for the treatment of the rare autoimmune disease, generalized myasthenia gravis (gMG). Additionally, argenx is continuing to co-develop its second product candidate, cusatuzumab (ARGX-110), with Janssen, targeting CD70 for rare and aggressive hematological cancers, for acute myeloid leukemia (AML) as well as high-risk myelodysplastic syndrome (MDS).